Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015184 | 0.89 | MAPT (0.58) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL2233749 | 0.85 | NPC1 (0.55) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL658301 | 0.82 | PDE3B (0.59) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| Bromide SCHEMBL15650437 | 0.81 | PDE3B (0.57) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL13859962 | 0.80 | CDK2 (0.40) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL24982426 | 0.78 | CHRNB2 (0.47) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL19553105 | 0.78 | PDE3B (0.42) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL7097550 | 0.77 | CYP11B1 (0.56) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL18173665 | 0.77 | NPC1 (0.50) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL16863063 | 0.74 | CYP11B1 (0.58) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023204308-A1 | OXAZEPINE DERIVATIVE | 帝人ファーマ株式会社 | 2023-10-26 | — | — | WO | claimed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | claimed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | claimed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | claimed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | claimed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | claimed |
| EP-2393806-B1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARM INC (US) | 2017-10-25 | — | — | EP | claimed |
| US-9796706-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | claimed |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | claimed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | claimed |
| EP-2252612-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-11-24 | — | — | EP | claimed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | claimed |
| WO-2009105712-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2009-08-27 | — | — | WO | claimed |
| EP-1003745-A1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY LLC (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999009030-A1 | NAPHTHYRIDINONES FOR INHIBITING PROTEIN TYROSINE KINASE AND CELL CYCLE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| WO-1994000450-A1 | CHROMANDERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | ZENECA LIMITED (GB) | 1994-01-06 | — | — | WO | claimed |
| WO-1993024501-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSINS ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| WO-1993024487-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN-II-ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| EP-0539066-A1 | Heterocyclic compounds useful as angiotensin II antagonists | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | CYP11B1 2940/4885CYP11B2 3755/4885PDE3B 2793/4885 |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | CYP11B1 2584/4885CYP11B2 2941/4885PDE3B 2325/4885 |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | CYP11B1 2940/4885CYP11B2 3755/4885PDE3B 2793/4885 |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | CYP11B1 2940/4885CYP11B2 3755/4885PDE3B 2793/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | CYP11B1 2584/4885CYP11B2 2941/4885PDE3B 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.